Cancer Chemotherapy and Pharmacology

, Volume 5, Issue 1, pp 67–69 | Cite as

Phase I evaluation of divided-dose vinblastine sulfate

  • Philip Schulman
  • Daniel R. Budman
  • Vincent Vinciguerra
  • Thomas J. Degnan
Original Articles Pharmacokinetics of Vinblastine


The known pharmacokinetics of vinblastine sulfate given by intermittent bolus dictate alternate dose schedules for prolonging the therapeutic levels. Herein, we have tested a divided dose schedule which shows out-patient feasibility, manageable toxicity, and encouraging responses.


Sulfate Cancer Research Dose Schedule Vinblastine Divided Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bruce WR, Meeker BE, Valeriote FA (1966) Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37: 233Google Scholar
  2. 2.
    Chirife AM, Studzinski GP (1978) Definition of the cell cycle segment with special sensitivity to vinblastine. Proc Exp Biol Med 157: 206Google Scholar
  3. 3.
    Dyke RW, Nelsen RL (1977) Phase I anti-cancer agents-Vindesine (desacetyl vinblastine amide sulfate). Cancer Treat Rev 4: 135Google Scholar
  4. 4.
    Gotlieb JA (1975) Phase I and phase II clinical trials, a critical research. Williams and Wilkens, Baltimore, p 485Google Scholar
  5. 5.
    Livingston RB, Carter SK (1970) Single agents in cancer chemotherapy. IFI/Plenum, New York Washington LondonGoogle Scholar
  6. 6.
    Owellen JB, Hartke CA, Hains F (1977) Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 37: 2597Google Scholar
  7. 7.
    Robertson JH, McCarthy GM (1969) Periwinkle alkaloids and platelet count. Lancet 2: 353Google Scholar
  8. 8.
    Southwest Oncology Group (1974) Cytarabine for acute leukemia in adults. Arch Intern Med 133: 251Google Scholar
  9. 9.
    Williams CJ, Carter SK (1978) Management of trials in the development of cancer chemotherapy. Br J Cancer 37: 434Google Scholar
  10. 10.
    Yap HY, Blumenschein GR, Hortobagyi GN, Tashima CK, Loo TL (1979) Continuous five day infusion vinblastine (VLB) in the treatment of refractory advanced breast cancer. Proceedings AACR/ASCO 20: C 179Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • Philip Schulman
    • 1
  • Daniel R. Budman
    • 1
  • Vincent Vinciguerra
    • 2
  • Thomas J. Degnan
    • 2
  1. 1.Don Monti Division of Oncology, Department of MedicineNorth Shore University HospitalManhasset
  2. 2.Department of MedicineCornell University Medical CenterNew YorkUSA

Personalised recommendations